Project Grant R21CA318463
Award Date 7/1/26
Completion Date 6/30/28
Dollars Obligated $374K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Columbus, OH 43210, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute (NCI), under the Cancer Biology Research program (CFDA 93.396), awarded The Ohio State University a $621,574 Project Grant effective July 1, 2026, through June 30, 2031, to investigate mitochondrial reprogramming mechanisms in tumor-associated macrophages (TAMs) as a strategy to counteract immunosuppression in the tumor microenvironment. The research will deliver fundamental scientific knowledge addressing a critical gap in cancer...
- Federal Project Grant Award Summary The National Cancer Institute awarded The Ohio State University a Project Grant of $157,500 under the Cancer Cause and Prevention Research program (CFDA 93.393) on July 15, 2025, with completion scheduled for June 30, 2027. This award supports research investigating the roles of the TIP60 chromatin remodeling complex in DNA double-strand break (DSB) repair mechanisms. The research focuses on understanding how the TIP60 complex, particularly through its KAT5...
- Federal Grant Award Summary The Ohio State University received a $384,524 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) awarded on June 17, 2026, with completion targeted by May 31, 2028. The grant supports pre-clinical research and development of a novel immunotherapeutic platform utilizing targeted prodrug cytokines for metastatic breast cancer treatment. The research addresses critical drug delivery and blood-brain barrier...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Ohio State University a Project Grant totaling $192,564 under the Cancer Research Manpower program (CFDA 93.398) effective September 1, 2025, through August 31, 2028. This award supports the development of chimeric antigen receptor (CAR) modified natural killer (NK) cell-based immunotherapy for the treatment of pediatric solid tumors. The research aims to advance NK cell engineering as a safer and more effective...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded $270,683 to the New York Genome Center, Inc. (NYGC) under the Cancer Biology Research program (CFDA 93.396) on May 5, 2026, with an ultimate completion date of April 30, 2029. This Project Grant funds the development and validation of Paired-Break-Seq, a novel high-throughput single-cell multiomics sequencing technique designed to simultaneously analyze DNA double-strand breaks (DSBs), single-strand breaks (SSBs), and...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Ohio State University a $449,222 Project Grant effective August 20, 2025, through July 31, 2030, under the Cancer Treatment Research program (CFDA 93.395). This award funds research to elucidate the cellular and molecular mechanisms by which PD-1H (Programmed Death-1 Homolog, also known as VISTA) mediates immune suppression in acute myeloid leukemia (AML) and to evaluate its potential as a therapeutic target. The...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded $182,755.00 to Cold Spring Harbor Laboratory through the Cancer Biology Research program (CFDA 93.396) to support research on genetic technology development for elucidating lineage plasticity mechanisms in cancer. The project, which commenced on August 21, 2025, and is scheduled for completion on July 31, 2030, will deliver advanced genetic screening technologies and methodologies designed to probe lineage identity...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $639,295 Project Grant to the Research Institute at Nationwide Children's Hospital under the Cancer Cause and Prevention Research program (CFDA 93.393) on May 8, 2026, with an ultimate completion date of April 30, 2031. This award funds research to elucidate the molecular mechanisms governing fusion oncoproteins derived from chromosomal translocations, specifically investigating how FET family proteins (FUS, EWSR1,...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the University of Alabama a $631,621 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop an integrated top-down proteomics and phosphoproteomics platform for analyzing patient-derived ovarian cancer spheroids. The award, effective August 13, 2025, through July 31, 2028, supports the creation of personalized intact proteome maps that characterize disease states and identify markers...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded The Ohio State University a $188,351 Project Grant under the Cancer Research Manpower program (CFDA 93.398) on September 3, 2025, with a completion date of August 31, 2028. This award supports research and career development activities focused on mutation-specific pan-KRAS (Kirsten rat sarcoma viral oncogene homolog) inhibitor signaling responses and anti-tumor effects. The project involves comprehensive genetic,...